← Company directoryNASDAQ · SEC EDGAR
Apogee Therapeutics, Inc.
APGEA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
Final trading day for Apogee Therapeutics
2 September was the final trading day for Apogee Therapeutics shares; APGE trading was halted at about 7:50 PM ET after hours. The AbbVie merger consideration is $135.11 in cash per share.
Nasdaq ↗Completion of the Apogee Therapeutics–AbbVie merger
The Apogee Therapeutics–AbbVie merger closed before the market opened on 3 September. Apogee shareholders will receive $135.11 in cash per share.
Nasdaq ↗Nasdaq suspension of Apogee Therapeutics shares
Following completion of the AbbVie merger, APGE trading was suspended from Nasdaq effective at the 4 September market open.
Nasdaq ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
APACRStoneBridge Acquisition II Corporation - RightsNASDAQ · SEC→APACUStoneBridge Acquisition II Corporation - UnitsNASDAQ · SEC→APCARKO Petroleum Corp.NASDAQ · SEC→APEIAmerican Public Education, Inc.NASDAQ · SEC→APIAgora, Inc. - ADSNASDAQ · SEC→APLDApplied Digital CorporationNASDAQ · SEC→APLMApollomics Inc. - Class A Ordinary SharesNASDAQ · SEC→APLMWApollomics Inc. - WarrantNASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.